碘利多酸 | 21766-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 碘利多酸
• 英文名称: 2-[2,4,6-triiodo-3-(2-oxo-pyrrolidin-1-yl)-benzyl]-butyric acid
• 英文别名: iolidonic acid；2-[[2,4,6-triiodo-3-(2-oxopyrrolidin-1-yl)phenyl]methyl]butanoic acid
• CAS: 21766-53-0
• 化学式: C₁₅H₁₆I₃NO₃
• 分子量: 639.01
• InChiKey: MJGWMPWEXXUAPD-UHFFFAOYSA-N

物化性质

• 沸点：
  675.7±55.0 °C(Predicted)
• 密度：
  2.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

文献信息

• Novel targeted compositions for diagnostic and therapeutic use
  申请人：——

  公开号：US20020159951A1

  公开（公告）日：2002-10-31

  Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compound, P comprises a hydrophilic polymer, and T comprises a targeting ligand which targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The compositions can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

  这是一种可用于诊断和治疗的新型靶向组合物。该组合物可能包含脂质、蛋白质或聚合物气体充填的囊泡，进一步包括一般式为L-P-T的新化合物，其中L包括疏水化合物，P包括亲水性聚合物，T包括靶向配体，可靶向组织、细胞或受体，包括心肌细胞、内皮细胞、上皮细胞、肿瘤细胞和糖蛋白GPIIbIIIa受体。该组合物可与诊断成像技术（如超声）以及治疗应用（如治疗性超声）结合使用。
• Particulate contrast media
  申请人：NYCOMED IMAGING AS

  公开号：EP0414287A1

  公开（公告）日：1991-02-27

  There is provided a magnetic resonance contrast medium comprising magnetically responsive particles and a physiologically tolerable osmoactive agent.

  提供了一种磁共振造影剂，它由磁响应颗粒和生理上可耐受的渗透剂组成。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• PARTICULATE CONTRAST MEDIA
  申请人：COCKBAIN, Julian Roderick Michaelson

  公开号：EP0483278A1

  公开（公告）日：1992-05-06
• CONTRAST MEDIA
  申请人：COCKBAIN, Julian Roderick Michaelson

  公开号：EP0619716A1

  公开（公告）日：1994-10-19